Literature DB >> 9047083

Serum levels and in situ expression of TNF-alpha and TNF-alpha binding proteins in inflammatory liver diseases.

U Spengler1, R Zachoval, H Gallati, M C Jung, R Hoffmann, G Riethmüller, G Pape.   

Abstract

Cells respond to tumour necrosis factor-alpha (TNF-alpha) via binding to 75-kDa (type A) and 55-kDa (type B) receptors which have different intracellular signalling pathways and can also circulate as soluble molecules. Both receptors are co-expressed in many tissues, but their relative contributions to cellular TNF responses is for most situations unknown. In patients with viral and non-viral inflammatory liver diseases serum TNF-alpha was determined by an immunoenzymetric assay and soluble type A and B TNF receptors (TNF-alpha r) by enzyme-linked immunological and biological assays (ELIBA). In addition, cellular expression of TNF and its binding proteins were studied in liver biopsies by an indirect immunoperoxidase technique. Secretion of TNF-alpha and upregulation of TNF-alpha r-A were particularly prominent in viral hepatitis. Strong TNF-alpha in-situ production by mononuclear cells could be demonstrated in liver biopsies from patients with acute viral hepatitis. However, TNF-alpha r-A was detected only on hepatocytes. Serum TNF-alpha r-A was elevated two-fold in relative abundance over TNF-alpha r-B and was correlated to serum TNF-alpha (r = 0.6464, P < 0.0001). Soluble TNF-alpha r levels normalized, when the viral hepatitis was cleared, and successful therapy of hepatitis B was associated with a temporary rise of TNF-alpha r-A during the initial flare of aminotransferase. Patients with alcoholic hepatitis had also evidence of TNF-alpha activation but clearly differed from patients with viral induced liver diseases: Soluble TNF-alpha r-A and TNF-alpha r-B were highly elevated in equal proportions. In situ analysis in liver biopsies revealed a distinctive pattern of TNF-alpha r expression with strong cytoplasmic staining for both TNF-alpha r-A and B on scattered hepatocytes in addition to infiltrating mononuclear cells. The data propose that TNF release during antiviral immune responses is predominantly associated with TNF-alpha r-A upregulation and shedding, whereas upregulation and shedding of TNF-alpha r-B is more prominent in alcoholic hepatitis. As cytotoxicity and apoptosis by TNF are mediated mainly via TNF-alpha r-B, our results are consistent with more severe TNF-alpha induced liver damage in alcoholic hepatitis as compared to viral hepatitis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9047083     DOI: 10.1006/cyto.1996.0115

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  7 in total

1.  Acute tumor necrosis factor-alpha-induced liver injury in the absence of tumor necrosis factor receptor-associated factor 1 gene expression.

Authors:  Gloria S Pryhuber; Heidie L Huyck; Jason M Roper; Judith Cornejo; Michael A O'Reilly; Robert H Pierce; Erdyni N Tsitsikov
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

2.  Tumor necrosis factor alpha signaling in the development of experimental murine pre-hepatic portal hypertension.

Authors:  Nicholas G Theodorakis; Yining N Wang; Jianmin Wu; Mary A Maluccio; Nicholas J Skill
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2010-03-08

3.  Tumor necrosis factor receptor 1 expression is upregulated in dendritic cells in patients with chronic HCV who respond to therapy.

Authors:  Raul Cubillas; Katherine Kintner; Frances Phillips; Nitin J Karandikar; Dwain L Thiele; Geri R Brown
Journal:  Hepat Res Treat       Date:  2010-08-03

Review 4.  Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.

Authors:  L H Calabrese; N Zein; D Vassilopoulos
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

5.  An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models.

Authors:  Maria A Graziewicz; Teresa K Tarrant; Brian Buckley; Jennifer Roberts; LeShara Fulton; Henrik Hansen; Henrik Ørum; Ryszard Kole; Peter Sazani
Journal:  Mol Ther       Date:  2008-05-06       Impact factor: 11.454

6.  Combined Intraperitoneal and Intrathecal Etanercept Reduce Increased Brain Tumor Necrosis Factor-Alpha and Asymmetric Dimethylarginine Levels and Rescues Spatial Deficits in Young Rats after Bile Duct Ligation.

Authors:  Jiunn-Ming Sheen; Yu-Chieh Chen; Mei-Hsin Hsu; You-Lin Tain; Hong-Ren Yu; Li-Tung Huang
Journal:  Front Cell Neurosci       Date:  2016-06-23       Impact factor: 5.505

7.  TNFα sensitizes hepatocytes to FasL-induced apoptosis by NFκB-mediated Fas upregulation.

Authors:  Laura Faletti; Lukas Peintner; Simon Neumann; Sandra Sandler; Thomas Grabinger; Sabine Mac Nelly; Irmgard Merfort; Chun-Hao Huang; Darjus Tschaharganeh; Tae-Won Kang; Florian Heinzmann; Luana D'Artista; Ulrich Maurer; Thomas Brunner; Scott Lowe; Lars Zender; Christoph Borner
Journal:  Cell Death Dis       Date:  2018-09-05       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.